An Open-label, Phase I Trial to Determine the Maximum-tolerated Dose and Investigate Safety, Pharmacokinetics, and Efficacy of BI 754091 in Patients With Advanced Solid Tumours

Trial Profile

An Open-label, Phase I Trial to Determine the Maximum-tolerated Dose and Investigate Safety, Pharmacokinetics, and Efficacy of BI 754091 in Patients With Advanced Solid Tumours

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2018

At a glance

  • Drugs BI 754091 (Primary)
  • Indications Bladder cancer; Breast cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 16 Apr 2018 Planned End Date changed from 29 May 2019 to 30 Mar 2021.
    • 16 Apr 2018 Planned primary completion date changed from 29 May 2019 to 30 Mar 2021.
    • 26 Jan 2018 Planned number of patients changed from 45 to 105.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top